Despite ‘curative’ surgery, with conventional adjuvant chemotherapy, which is the current standard for ALK, less than 50% of lung cancer patients are cured long term and probably fewer again in a pure ALK population, with an inherently higher risk of occult micro-metastatic disease-promoting relapse (131). This evidence concerns the gene ALK and lung carcinoma.